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S U M M A R Y
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) blood stream infections (BSI) are a major
health care problem accounting for a large percentage of nosocomial infections. The aim of this study was
to identify risk factors associated with 30-day mortality in patients with MRSA BSI.
Methods: This was a retrospective study performed in Southeast Michigan. Over a 9- year period, a total of
1,168 patients were identified with MRSA BSI. Patient demographics and clinical data were retrieved and
evaluated using electronic medical health records.
Results: 30-day mortality during the 9-year study period was 16%. Significant risk factors for 30-day
mortality were age, cancer, heart disease, neurologic disease, nursing home residence and Charlson score
>3 with Odds Ratio (OR) of 1.03 (CI 1.02–1.04), 2.29 (CI 1.40–3.75), 1.78 (CI 1.20–2.63), 1.65 (CI 1.08–2.25),
1.66 (CI 1.02  2.70) and 1.86 (CI 1.18  2.95) correspondingly. Diabetes mellitus, peripheral vascular
disease (PVD), and readmission were protective factors for 30-day mortality with OR of 0.53 (CI 0.36–
0.78), 0.46 (CI 0.26–0.84) and 0.13 (CI0.05  0.32) respectively.
Conclusions: Our study identified significant risk factors for 30-day mortality in patients with MRSA BSI.
Interestingly, diabetes mellitus, PVD and readmission were protective effects on 30-day mortality. There
was no statistically significant variability in 30-day mortality over the 9-year study period.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
MRSA infection was first described in 1961 and continues to be a
major public health concern, accounting for significant nosocomial
and increasing community-acquired infections (Barber, 1961;
Pastagia et al., 2012). From 1993 to 2009, septicemia related
hospitalizations increased to 153 percent, adding to healthcare
cost, up to 15.4 billion dollars (Elixhauser et al., 2011). Recent data
show that the incidence is still increasing (Elixhauser et al., 2011).
In the 2013 National Center for Health Statistics Report showed an
overall decrease in mortality but an increase in bloodstream
related deaths by 17% (Hall et al., 2013). In the 2010 National
Healthcare Safety Network (NHSN) report on antimicrobial-
resistant pathogens associated with healthcare infections, S.
aureus was the most common pathogen reported, of which
54.6% were methicillin-resistant (Sievert et al., 2013). MRSA BSI
can cause devastating complications with mortality reported up to
39% (Pastagia et al., 2012; Keynan and Rubinstein, 2013; Mansur
et al., 2012; Wi et al., 2012; Lee et al., 2013; Gasch et al., 2013a).
Identifying risk factors associated with mortality is essential to
improving patient outcomes. Studies have shown that the most
important factors determining patient outcomes in MRSA BSI are
age, presence of comorbidities, and appropriate initial antibiotic
treatment (Pastagia et al., 2012; Keynan and Rubinstein, 2013; Ok
et al., 2013). This study aims to identify possible predictors of 30-
day mortality in MRSA BSI patients and to evaluate changes in
mortality rate over a 9 year period.
* Corresponding author.
http://dx.doi.org/10.1016/j.ijid.2017.05.010
1201-9712/© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Methods
Study Design and Patient Identification
This was a retrospective study performed at an integrated 4-
hospital health system in southeast Michigan. The primary
outcome of this study was 30-day all-cause mortality in patients
with MRSA BSI. All patients  18 years of age with confirmed MRSA
BSI were identified over a 9-year period, from July 2005 to June
2014, via review of microbiology laboratory records. Electronic
medical health records were utilized to obtain clinical information,
patient demographics and 30-day mortality. Thirty-day all cause
mortality was defined as death within 30 days of index blood
culture. Patient demographics and comorbidities included: age,
gender, presence of immunosuppressive disease, cancer, heart
disease, gastrointestinal (GI) disease, neurological disease, renal
disease, diabetes mellitus, human immunodeficiency virus (HIV),
neutropenia, solid organ transplant recipient, intravenous drug use
(IVDA), peripheral vascular disease (PVD) and connective tissue
disease. The following healthcare exposures were analyzed: prior
hospitalization including admission to intensive care unit (ICU),
recent surgery within the past 1 year, nursing home residence
(NHR), and presence of indwelling central venous catheter (CVC).
Source of acquisition was categorized as follows: CVC related,
osteomyelitis, endocarditis, graft infection, skin or wound infec-
tions, intra-abdominal (IA), respiratory, urinary tract (UTI) or
undetermined source. Duration of bacteremia and recurrence were
evaluated. Recurrence was defined as positive blood culture within
30 days of completing treatment; duration of bacteremia was
divided in 3 groups: 3 days, 4–6 days and  7 days. Patients with
recurring positive blood cultures during one admission were
included once. Readmission was defined as any infection-related
readmissions within 30 days of completing therapy. The Charlson
Comorbidity Index was calculated to compare patients’ comor-
bidities and 30-day mortality (Charlson et al., 1987).
Statistical Analysis
Continuous data were described using means and standard
deviations, while all categorical data were presented as counts and
percentages. Five patients were excluded from the analysis
because of incomplete data. Univariate two-group tests were
performed to compare clinical and demographic data between
patients who expired within 30 days from index blood culture with
alive patients. All predictors of mortality with univariate P-value
<0.2 were included in a multivariable logistic regression model. A
final model was produced using manual backwards selection,
meaning non-significant predictors were removed one by one in
descending P-value order and the model re-run each time until
each predictor remaining was significant. Variability in 30-day all-
cause mortality over the 9-year study period was determined using
Table 1
Univariate and Multivariate Logistic Regressionn Analysis.
Predictor Demographics and Clinical Characteristics Univariate Logistic Regression Multivariate Logistic Regression
Unadjusted OR 95% CI P-Value Adjusted OR 95% CI P-Value
Age, years, mean(SD) 60.3 (17.6) 1.04 1.03-1.05 <0.001 1.03 1.02-1.04 <0.001
Gender, male 689 (59%) 1.13 0.83-1.55 0.4417
Race
African American 694 (60%)
Caucasian 407 (35%)
Other 56 (5%)
Cancer 140 (12%) 2.73 1.84-4.07 <0.0001 2.29 1.40-3.75 0.001
Connective tissue 23 (2%) 1.12 0.38-3.36 0.8341
CVC 127 (11%) 0.61 0.34-1.08 0.0913
Diabetes 467 (40%) 0.75 0.54-1.04 0.0800 0.53 0.36-0.78 0.0015
Duration of bacteremia, days (SD) 3.9 1.32 0.78-2.23 0.3099
GI disease 238 (20%) 1.06 0.73-1.55 0.7486
Heart disease 329 (28%) 2.25 1.64-3.10 0.0001 1.78 1.20-2.63 0.0039
HIV 35 (3%) 0.30 0.07-1.26 0.1009
Immunosuppressive disease 75 (6%) 1.83 1.06-3.15 0.0306
IV drug use 206 (18%) 0.40 0.24-0.68 0.0006
Neurologic disease 236 (20%) 2.44 1.73-3.43 0.0001 1.65 1.08-2.52 0.02
Neutropenia 13 (1%) 3.20 1.04-9.89 0.0432
Nursing home resident 129 (11%) 2.67 1.77-4.02 <0.0001 1.66 1.02-2.70 0.0421
Prior hospitalization 597 (51%) 1.25 0.92-1.70 0.1599
Prior ICU stay 183 (16%) 1.31 0.88-1.96 0.1876
Prior surgery 102 (9%) 1.10 0.65-1.89 0.7165
PVD 149 (13%) 0.66 0.39-1.11 0.1191 0.46 0.26-0.84 0.0106
Readmit infection 169 (14%) 0.13 0.05-0.33 <0.0001 0.13 0.05-0.32 <0.001
Recurrence 30d 84 (7%) 0.24 0.09-0.65 0.0055
Renal disease 550 (47%) 1.29 0.95-1.76 0.1077
Respiratory disease 208 (18%) 2.10 1.47-3.01 <0.0001
Solid organ transplant 31 (3%) 1.79 0.79-4.05 0.1655
Source: Graft 31 (3%) 1.22 0.49-3.01 0.6675
Source: CVC 244 (21%) 0.63 0.41-0.96 0.0316 0.39 0.24-0.63 0.0001
Source: IE 0 N/A N/A
Source: IA 10 (1%) 2.18 0.56-8.52 0.2609
Source: None 247 (21%) 1.91 1.36-2.70 0.0002
Source: Respiratory 97 (8%) 2.26 1.41-3.62 0.0007
Source: Skin/Wound 370 (32%) 0.51 0.35-0.75 0.0005 0.48 0.31-0.71 0.001
Source: GU 61 (5%) 1.14 0.58-2.24 0.6986 0.40 0.18-0.88 0.022
Source: Osteomyelitis 7 (1%) 0.00 0.001- > 999 0.9838
Source: Endocarditis 106 (9%) 0.89 0.51-1.55 0.6779
Charlson Score, N, mean (SD) 1154, 3.2 (2.4) 1.77 1.11-1.25 <0.001
Charlson Score Category (> = 3 vs <3) 2.40 1.69-3.40 <0.001 1.86 1.18-2.95 0.0079
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a chi-square test. All statistical analyses were completed using SAS
9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Over the 9-year period there were 1,168 individual patients
with MRSA BSI, of which 193 (16%) expired within 30 days of index
blood culture. Over the 9-year period there was no significant
variability in 30-day mortality (p = 0.1934).
Results from univariate and multivariate logistic regression
models evaluating the association between risk factors and 30-day
mortality are shown in Table 1. The following risk factors were
associated with increased risk of 30-day mortality: cancer OR 2.29
(CI 1.40-3.75 p value 0.001), heart disease OR 1.78 (CI 1.20-2.63 p-
value 0.0039), neurologic disease OR 1.65 (CI 1.08-2.52 p-value
0.02), nursing home residence OR 1.66 (CI 1.02-1.70 p value
0.0421), and Charlson score >3 OR 1.88 (CI 1.19-2.97 p value
0.0068). Age was a statistically significant risk factor (p-value
<0.001). The odds of 30-day mortality increased by 2.9% for every
year increase in age when controlling for other variables. Diabetes,
PVD, and readmission were protective factors for 30-day mortality
with OR of 0.60 (CI 0.42-0.86 p-value 0.0056), 0.53 (CI 0.30 0.93
p-value 0.0277), 0.12 (CI 0.05–0.30 p- value <0.001) respectively.
There was a relationship between lower mortality and infection
sources including CVC OR 0.39 (CI 0.24-0.63 p value 0.0001), skin/
wound OR 0.48 (CI 0.31-0.71 p value 0.001) and GU OR 0.40 (CI
0.18-0.88 p value 0.022).
Discussion
Consequences of MRSA bacteremia are devastating with
increase in hospital stay, morbidity, and mortality. Therefore,
early identification of MRSA BSI is important to optimize patient
outcomes (Lee et al., 2013; Gasch et al., 2013a; Bassetti et al., 2011;
Hernandez et al., 2015; Gasch et al., 2013b). Prior studies have
shown two modifiable risk factors for 30-day mortality: 1)
appropriate empiric antimicrobial therapy, 2) prompt removal of
focus (Keynan and Rubinstein, 2013; Lee et al., 2013; Gasch et al.,
2013a; Ok et al., 2013). Notably, with time we found no
improvement in overall mortality over time despite advancement
in antimicrobial treatment. Thus far, the role of different
antimicrobial agents against MRSA infection in clinical setting is
uncertain.
The strength of this study is a large sample size with
comprehensive clinical data over an extended period of time.
Despite advances in medical therapy, use of newer antibiotics, and
changes in patient characteristics and strains, we did not find any
statistically significant change in the rate of 30-day mortality over
the 9-year study period. Our study found 16.5% all cause 30-day
mortality in MRSA BSI; this is lower than rates reported in other
studies, which vary between 21–39% (Sievert et al., 2013; Wi et al.,
2012; Gasch et al., 2013a; Ok et al., 2013; Gasch et al., 2013b).
Our study showed age and cardiac disease as risk factors for 30-
day mortality which is consistent with findings in other studies
(Pastagia et al., 2012; Mansur et al., 2012; Ok et al., 2013; Gasch
et al., 2013b). A study evaluating outcomes in patients over 65 year
of age with community onset bacteremia found 52 out of 2,065
(2.51%) patients with MRSA BSI. Although the most common
pathogen isolated was Escherichia coli, MRSA had the highest
mortality (28%). Mortality was significantly higher in patients over
75 year of age, and administration of inappropriate antibiotic
treatment (Gasch et al., 2013b). This stresses the importance of
identifying these patients early in order to improve their outcomes.
Our analysis found that nursing home residence increased the risk
of 30 day mortality, which is likely due to advanced age and
increased number of comorbidities.
Contrary to other studies, we found that cancer was a
significant risk factor for 30-day mortality with an OR of 2.84
(1.82–4.44 p-value <0.001). Various studies have reported that the
presence of a previous rapid fatal underlying disease is an
important risk factor, but only one study analyzed cancer as an
independent risk factor which was not statistically significant (Lee
et al., 2013; Ok et al., 2013; Gasch et al., 2013b). Cancer, as well as
other conditions, is included in the Charlson weighted index of
comorbidity score. Although it can be a good tool that can help
clinicians identify patients who are at increased risk for early
mortality due to MRSA BSI, other factors such as source of
acquisition are not included (Retamar et al., 2012; Lesens et al.,
2003; Charlson et al., 1987).
Another study found that persistent bacteremia (defined as
positive blood cultures >7 days) had greater mortality than non-
persistent bacteremia 58.1% vs. 16.2% (p-value <0.001) (Hernan-
dez et al., 2015). However, our study did not find duration of
bacteremia to be a statistically significant risk factor for 30-day
mortality. All other risk factors that were evaluated including
presence of immunosuppressive disease, GI disease, renal disease,
diabetes, HIV status, neutropenia, solid organ transplant recipi-
ent, IVDA, connective tissue disease, ICU stay, and prior surgery
were not significantly associated with 30-day mortality. Contin-
uous observation of patients with MRSA BSI is essential to
improve our understanding of risk factors associated with 30-day
mortality.
In our study diabetes and PVD were protective factors for 30-
day mortality in patients with MRSA BSI. Other studies included
diabetes in their evaluation of risk factors, finding them to be
protective factors, though only one found it to be statistically
significant (Pastagia et al., 2012; Lee et al., 2013; Gasch et al.,
2013a). This is an unexpected finding, but we believe that it can be
associated with the source of infection. Patients with PVD and
diabetes are usually less acutely ill and present with skin/wound
infections which are more easily managed, and started earlier on
appropriate antibiotic treatment. There has been recent research
on hypoxia inducible factor 1 (HIF-1) playing an important role in
the innate response to infections (Bento and Pereira, 2011; Shalova
et al., 2015). HIF-1 is a transcription factor that is involved in energy
metabolism, cellular adaptation to hypoxia, and immune response.
Recent studies have shown that hyperglycemia destabilizes HIF-1,
which could contribute to diabetic complications such as
infections (Bento and Pereira, 2011; Howangyin and Silvestre,
2014). T. Bhandari et al and other groups are conducting research
into the possibility of having HIF-1 as a therapeutic target, which
would provide increased treatment options to patients with BSI
(Bhandari and Nizet, 2014; Okumura et al., 2012; Zeitouni et al.,
2016; Li et al., 2014).
We also found that readmission due to infection is a protective
factor. The reason of this was not determined, however, patients
who were readmitted because of MRSA infection would have
probably received an earlier and better management, which may
have prevented progression of disease, resulting in a decreased
mortality. Source of infection is an important mortality risk factor.
Our study found that skin/wound, GU, and CVC source of infection
are protective factors for 30-day mortality. Further studies
are needed in order to understand the causality of these
relationships.
A limitation of this study was that we did not have access to
information regarding ID consultation. All patients with MRSA
bacteremias were treated with vancomycin or daptomycin, but we
do not have information regarding timing of initial treatment.
Further studies are needed to evaluate the effects of appropriate
initial antibiotic treatment in high risk patients such as patients
with cancer, heart and neurologic disease. We did not include
MRSA strain types and vancomycin MICs as factors in our analysis.
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Conclusions
During the 9-year study period we did not find any statistically
significant variability in 30-day mortality. Our study showed that
age, cancer, heart disease, neurologic disease, nursing home
residence and Charlson score greater than 3 are risk factors for 30-
day mortality in patients with MRSA BSI. These findings can help
clinicians correlate patient risk factors with poor outcomes and
provide early optimal management, including removal of devices,
focus or other modifiable risk factors. Further prospective studies
are needed to examine this subset of patients, in order to design
interventions that can improve outcomes. We found that diabetes,
PVD and readmission were statistically significant protective
factors for 30-day mortality, though we believe that this is due
to the source and severity of infection. Continuous surveillance of
patients with multidrug resistant organism infections is essential
for our health care system.
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